Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
As the MAO-B inhibitor rasagiline is able to improve motor skills it might have positive
effects on sleep disruption by reducing nocturnal akinesia. As it was reported to cause only
minor sleep disruption in PD Patients, it might be able to improve sleep architecture. The
investigators thus study the effects of Rasagiline on sleep disturbances measured by
polysomnographic (PSG) evaluation of sleep efficacy and PDSS-2. Secondary measures are other
sleep variables measured by PSG, sleep quality and daytime sleepiness assessed by
standardized scales as well as cognitive function, depression and QoL index.
Phase:
Phase 4
Details
Lead Sponsor:
Technische Universität Dresden
Collaborators:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries